As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare technology industry, including GoodRx (NASDAQ: GDRX) and its peers.

Healthcare technology companies develop software, data analytics, and digital platforms supporting clinical operations, administrative functions, and patient engagement across healthcare systems. Tailwinds include healthcare digitization driving demand for electronic health records, telehealth platforms, and AI-powered diagnostic tools. Regulatory incentives promote interoperability and data sharing, while labor shortages increase automation demand. Headwinds include lengthy sales cycles with risk-averse healthcare buyers, complex regulatory requirements including data privacy compliance, and integration challenges with legacy systems. Competition from established technology giants entering healthcare and reimbursement uncertainties for digital health solutions add market complexity.

The 7 healthcare technology stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 1.6% while next quarter’s revenue guidance was in line.

Thankfully, share prices of the companies have been resilient as they are up 5.5% on average since the latest earnings results.

GoodRx (NASDAQ: GDRX)

Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ: GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.

GoodRx reported revenues of $194 million, down 4.4% year on year. This print exceeded analysts’ expectations by 4.9%. Overall, it was a strong quarter for the company with an impressive beat of analysts’ revenue estimates and full-year revenue guidance slightly topping analysts’ expectations.

GoodRx delivered the slowest revenue growth of the whole group. Interestingly, the stock is up 6.8% since reporting and currently trades at $2.75.

Is now the time to buy GoodRx? Access our full analysis of the earnings results here, it’s free.

Best Q1: Omnicell (NASDAQ: OMCL)

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ: OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Omnicell reported revenues of $309.9 million, up 14.9% year on year, outperforming analysts’ expectations by 1.8%. The business had an exceptional quarter with EBITDA guidance for next quarter exceeding analysts’ expectations and a beat of analysts’ EPS estimates.

The market seems happy with the results as the stock is up 6.7% since reporting. It currently trades at $40.14.

Is now the time to buy Omnicell? Access our full analysis of the earnings results here, it’s free.

Weakest Q1: Hims & Hers Health (NYSE: HIMS)

Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE: HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.

Hims & Hers Health reported revenues of $608.1 million, up 3.8% year on year, falling short of analysts’ expectations by 1.4%. It was a slower quarter as it posted a significant miss of analysts’ EPS estimates and EBITDA guidance for next quarter missing analysts’ expectations significantly.

Hims & Hers Health delivered the weakest full-year guidance update in the group. The company added 73,000 customers to reach a total of 2.58 million. Interestingly, the stock is up 7.8% since the results and currently trades at $31.41.

Read our full analysis of Hims & Hers Health’s results here.

Astrana Health (NASDAQ: ASTH)

Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ: ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.

Astrana Health reported revenues of $965.1 million, up 55.6% year on year. This result topped analysts’ expectations by 1.9%. More broadly, it was a satisfactory quarter as it also recorded a beat of analysts’ EPS estimates but full-year revenue guidance slightly missing analysts’ expectations.

Astrana Health pulled off the fastest revenue growth among its peers. The stock is up 5.4% since reporting and currently trades at $38.02.

Read our full, actionable report on Astrana Health here, it’s free.

Tandem Diabetes (NASDAQ: TNDM)

With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ: TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels.

Tandem Diabetes reported revenues of $247.2 million, up 5.5% year on year. This number surpassed analysts’ expectations by 3.2%. Overall, it was a very strong quarter as it also recorded a beat of analysts’ EPS and revenue estimates.

Tandem Diabetes achieved the highest full-year guidance raise among its peers. The stock is down 9.3% since reporting and currently trades at $16.75.

Read our full, actionable report on Tandem Diabetes here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand-wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.